Predictive markers in breast cancer - the future

被引：24

作者：

Faratian, D. ^{[1
]}

Bartlett, J. ^{[1
]}

机构：

[1] Edinburgh Canc Res Ctr, Endocrine Canc Grp, Edinburgh EH4 2XR, Midlothian, Scotland

来源：

HISTOPATHOLOGY | 2008年 / 52卷 / 01期

关键词：

clinical trial; predictive biomarkers; PTEN; RTK inhibitors; topoisomerase II; trastuzumab;

D O I：

10.1111/j.1365-2559.2007.02896.x

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The published literature is awash with examples of new tissue biomarkers promising to predict responses to therapy in breast cancer patients. However, few, if any, of these progress from the laboratory to the clinic. In this review we discuss some of the reasons for this, illustrating our discussion with a selection of biomarkers which are in development and which may be candidates for clinical application within the next few years (topoisomerase II alpha, epidermal growth factor receptor, AKT, phosphatase and tensin homologue). In particular, we explore how our ever increasing knowledge of molecular and pathway biology is facilitating hypothesis-driven biomarker discovery, and the statistical considerations which need to be addressed in order to validate new candidate biomarkers adequately.

引用

页码：91 / 98

页数：8

共 65 条

[1]

Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0

[2] The clinical evaluation of HER-2 status: which test to use? [J].

Bartlett, J ;

Mallon, E ;

Cooke, T .

JOURNAL OF PATHOLOGY, 2003, 199 (04) :411-417

[3]

BARTLETT JMS, 2006, ADV BREAST CANC, V3, P76

[4]

BARTLETT JMS, 2005, ADV BREAST CANC, V2, P11

[5] Activated ERK1/2 and phosphorylated oestrogen receptor α are associated with improved breast cancer survival in women treated with tamoxifen [J].

Bergqvist, Jenny ;

Elmberger, Goran ;

Ohd, John ;

Linderholm, Barbro ;

Bjohle, Judith ;

Hellborg, Henrik ;

Nordgren, Hans ;

Borg, Anna-Lena ;

Skoog, Lambert ;

Bergh, Jonas .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (08) :1104-1112

[6] Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas [J].

Burris, HA ;

Hurwitz, HI ;

Dees, EC ;

Dowlati, A ;

Blackwell, KL ;

O'Neil, B ;

Marcom, PK ;

Ellis, MJ ;

Overmoyer, B ;

Jones, SF ;

Harris, JL ;

Smith, DA ;

Koch, KM ;

Stead, A ;

Mangum, S ;

Spector, NL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5305-5313

[7] Bad expression predicts outcome in patients treated with tamoxifen [J].

Cannings, Elizabeth ;

Kirkegaard, Tove ;

Tovey, Sian M. ;

Dunne, Barbara ;

Cooke, T. G. ;

Bartlett, John M. S. .

BREAST CANCER RESEARCH AND TREATMENT, 2007, 102 (02) :173-179

[8] Gefitinib in pretreated non-small-cell lung cancer (NSCLC):: Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC [J].

Cappuzzo, F ;

Gregorc, V ;

Rossi, E ;

Cancellieri, A ;

Magrini, E ;

Paties, CT ;

Ceresoli, G ;

Lombardo, L ;

Bartolini, S ;

Calandri, C ;

De Rosa, M ;

Villa, E ;

Crinò, L .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2658-2663

[9] Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases [J].

Carter, TA ;

Wodicka, LM ;

Shah, NP ;

Velasco, AM ;

Fabian, MA ;

Treiber, DK ;

Milanov, ZV ;

Atteridge, CE ;

Biggs, WH ;

Edeen, PT ;

Floyd, M ;

Ford, JM ;

Grotzfeld, RM ;

Herrgard, S ;

Insko, DE ;

Mehta, SA ;

Patel, HK ;

Pao, W ;

Sawyers, CL ;

Varmus, H ;

Zarrinkar, PP ;

Lockhart, DJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) :11011-11016

[10] Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer [J].

Chan, S .

BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1420-1424

← 1 2 3 4 5 6 7 →